Atorvastatin therapy and serum 25(ОН)d level in women with abdominal obesity and dyslipidemia

Objective. Recent studies showed that statin therapy in patients with cardiovascular diseases (CVD) could increase serum 25(OH)D level. However, data remain unclear. the aim of the study was to assess serum 25(OH)D level in patients with abdominal obesity and dyslipidemia before and after atorvastatin therapy. Design and methods. We included 66 women, aged 41 to 57 years, with abdominal obesity and dyslipidemia. The group 1 included 45 women with more than two CVD risk factors and received atorvastatin treatment, and the group 2 (control group) included 21 women. All patients underwent anthropometric measurements (body weight, height, body mass index, waist and hip circumferences), laboratory (serum lipid profile, fasting plasma glucose, C-reactive protein, alaninaminotransferase and aspartataminotransferase, creatine-phosphokinase levels) and instrumental methods (diastolic and systolic blood pressure) at baseline and after six months. Results. Our study showed vitamin D deficiency in 62,1 % participants. Atorvastatin therapy was associated with the decrease in atherogenic lipoproteins and increase in serum 25(OH)D level by 6,0 ng/ml (40,3 %). We did not find correlations between increase in 25(OH)D level with a decrease in total cholesterol, low-density lipoproteins and triglycerides (p > 0,05). Conclusions. Our study shows that 6-month therapy with atorvastatin (40 mg per day) associated with the decrease in atherogenic lipoprotein levels and increase in serum 25(OH)D concentration.

25(OH)D, abdominal obesity, dyslipidemia, atorvastatin

1. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370 (9602):1829–1839. doi:10.1016/S0140-6736(07)61778-4

2. Busch N, Kelsberg G, Kendall SK, Krist A. Do statins reduce the risk of stroke? J Fam Pract. 2004;53(7):567–586. doi:10.1056/NEJMoa061894

3. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, García FA et al. Statin use for the primary prevention of cardiovascular disease in adults. US preventive services task force recommendation statement. JAMA. 2016;316(19):1997–2007. doi:10.1001/jama.2016.15450

4. Quek RGW, Fox KM, Wang L, Li L, Gandra SR, Wong ND. A US claims-based analysis of real-world lipid-lowering treatment patterns in patients with high cardiovascular disease risk or a previous coronary event. Am J Cardiol. 2016;117(4):495–500. doi:10.1016/j.amjcard.2015.11.035

5. Российские рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Атеросклероз и дислипидемии. 2012;8 (2):61–94. doi:10.15829/1560-4071-2017-5-7-77 [Russian recommendations on diagnostics and corrections of lipid exchange disturbances with the purpose to prevent and to treat atherosclerosis. Atherosclerosis and dyslipidemias. 2012;8(2):61–94. In Russian. doi:10.15829/1560-4071-2017-5-7-77].

6. Pinelli N, Jaber L, Brown M, Herman W. Serum 25-hydroxy vitamin D and insulin resistance, metabolic syndrome and glucose intolerance among Arab Americans. Diabetes Care. 2010;33 (6):1371–1375. doi:10.2337/dc09-2199

7. Strange RC, Shipman KE, Ramachandran S. Metabolic syndrome: a review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes. 2015;6(7):896–911. doi:10.4239/ wjd.v6.i7.896

8. DeMille DM, Piscitelli M, Ocker A, Vuong C, Hartner L, Lynch MP. Vitamin D deficiency in the oncology setting. J Community Support Oncol. 2014;12(1):13–19. doi:10.12788/jcso.0004

9. Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. J Clin Rev Allergy Immunol. 2013;45(2):256–266. doi:10.1007/s12016012-8342-y

10. Каронова Т. Л., Цветкова Е. В., Клюшина А. А., Михеева Е. П., Беляева О. Д., Костарева А. А. и др. Уровень 25(ОН) витамина D и компоненты метаболического синдрома у женщин репродуктивного возраста при различном генотипе ApaI полиморфизма гена рецептора витамина D. Артериальная гипертензия. 2013;19(1):67–75. [Karonova TL, Tsvetkova EV, Klushina AA, Mikheeva EP, Belyaeva OD, Kostareva AA et al. Vitamin D and components of metabolic syndrome in women of reproductive age with different genotypes of vitamin D receptor gene ApaI polymorphism. Arterial’naya Gipertenziya = Arterial Hypertension. 2013;19(1):67–75. In Russian].

11. Lee JH, O’Keefe JH, Donald DB, Hensrud D, Michael MP, Holick F. Vitamin D Deficiency: an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52 (24):1949–1956. doi:10.1016/j.jacc.2008.08.050

12. Каронова Т. Л., Гринева Е. Н., Никитина И. Л., Цветкова Е. В., Тодиева А. М., Беляева О. Д. и др. Распространенность дефицита витамина D в Северо-Западном регионе РФ среди жителей г. Санкт-Петербурга и г. Петрозаводска. Остеопороз и остеопатии. 2013; 16(3):3–7. doi:10.14341/osteo201333-7 [Karonova TL, Grineva EN, Nikitina IL, Tsvetkova EV, Todieva AM, Belyaeva OD et al. The prevalence of vitamin D deficiency in the North-West region of the Russian Federation among residents of St Petersburg and Petrozavodsk. Osteoporosis and Osteopathy. 2013;16(3):3–7. In Russian. doi:10.14341/osteo201333-7].

13. Каронова Т. Л., Михеева Е. П., Красильникова Е. И., Беляева О. Д., Буданова М. В., Галкина О. В. и др. Дефицит витамина D — фактор риска развития ожирения и сахарного диабета 2-го типа у женщин репродуктивного возраста. Артериальная гипертензия. 2012;18(1):25–31. [Karonova TL, Mikheeva EP, Krasilnikova EI, Belyaeva OD, Budanova MV, Galkina OV et al. Vitamin D deficiency is a risk factor for obesity and type 2 diabetes mellitus in reproductive age women. Arterial’naya Gipertenziya = Arterial Hypertension. 2013;19(1):67–75. In Russian].

14. Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther. 2009;23(4):295–299. doi:10.1007/ s10557-009-6181-8

15. Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. Cardiovasc Pharmacol Ther. 2012;17(4):382–386. doi:10.1177/ 1074248412439470

16. Holic MF. High prevalence of vitamin D inadequancy and implications for health. Mayo Clin Proc. 2006;81(3):353–373. doi:10.4065/81.3.353

17. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha, 25-dihydroxyvitamin D(3): implications for druginduced osteomalacia. Mol Pharmacol. 2006;69(1):56–65. doi:10. 1002/jbmr.1839

18. Mazidi M, Rezaie P, Vatanparast H, Kengne AP. Effect of statins on serum vitamin D concentrations: a systematic review and meta-analysis. Eur J Clin Invest. 2017;47(1):93–101. doi:10.1111/ eci.12698

19. Sahebkar A, Reiner Z, Simental-Mendia LE, Ferretti G, Della Corte C, Nobili V. Impact of statin therapy on plasma vitamin D levels: a systematic review and meta-analysis. Curr Pharm Des. 2017;23(6):861–869. doi:10.2174/1381612822666161006150542

20. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012. doi:10.1093/eurheartj/ehs 092

21. Global Database on Body Mass index. BMI Classification. Source: Adapted from WHO 1995, WHO 2000 and WHO 2004. doi:10.1097/NT.0000000000000092

22. The IDF consensus worldwide definition of the metabolic syndrome, International Diabetes Federation, 2006. Available from: https://www.idf.org/e-library/consensus-statements/60-idfconsensus- worldwide-definitionof-the-metabolic-syndrome.html.

23. De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM et al. Endotext. South Dartmouth (MA): MD Text.com, Inc.; 2000-. Available from: www.endotext.org.

24. Holic MF. Vitamin D deficiency. N Engl J Med. 2007;357 (3):266–281. doi:10.1093/ajcn/87.4.1080S

25. Ertugrul DT, Yavuz B, Cil H, Ata N, Akin KO, Kucukazman M et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther. 2011;29(2):146–152. doi:10.1111/j.1755-5922. 2010.00141.x

26. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet. 1993;24(3):195– 202. doi:10.2165/00003088-199324030-00002

27. Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM. 2012;105(5):487–491. doi:10.1093/qjmed/hcs001

28. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 1995;333(10):664–665. doi:10.1056/NEJM1995 09073331015

29. Grimes DS. Are statins analogues of vitamin D? Lancet. 2006;368(9529):83–86. doi:10.1016/S0140-6736(06)68971-X

30. Reboul E, Goncalves A, Comera C, Bott R, Nowicki M, Landrier JF et al. Vitamin D intestinal absorption is not a simple passive diffusion: evidences for involvement of cholesterol transporters. Mol Nutr Food Res. 2011;55(5):691–702. doi:10.1002/ mnfr.201000553

31. Zhao SP, Wu ZH, Hong SC, Ye HJ, Wu J. Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Clin Chim Acta. 2006;365(1–2):119–124. doi:10.1016/j.cca.2005.08.006

32. Kavarić S, Vuksanović M, Bozović D, Jovanović M, Jeremić V, Radojicić Z et al. Body weight and waist circumference as predictors of vitamin D deficiency in patients with type 2 diabetes and cardiovascular disease. Vojnosanit Pregl. 2013;70(2): 163–169.